International Journal of Chemical Science
www.chemicaljournals.com
Online ISSN: 2523-2843, Print ISSN: 2523-6075
Received: 06-06-2025, Accepted: 06-07-2025, Published: 21-07-2025
Volume 9, Issue 2, 2025, Page No. 16-21

Nanotechnology is transforming the pharmaceutical landscape by enabling targeted drug delivery, improved bioavailability, and reduced side effects.

Shilpa VP*, Sirrajudheen MK, Akshaya P, Fathima Rabwa PT, Jaseeda Thelakkadan
Department of Pharmaceutics, Jamia Salafiya pharmacy college, Malappuram, kerala, India

Abstract
Nanotechnology has revolutionized the pharmaceutical landscape by enabling the development of advanced drug delivery systems that address many limitations of conventional therapeutics. Nanocarriers such as liposomes, polymeric nanoparticles, dendrimers, micelles, and solid lipid nanoparticles offer unique advantages, including enhanced solubility and permeability, controlled and sustained drug release, and the ability to target specific tissues or cells. These features significantly improve the bioavailability and therapeutic efficacy of drugs, particularly those with poor solubility or challenging pharmacokinetic profiles. Furthermore, nanocarriers can overcome biological barriers such as the blood-brain barrier and gastrointestinal tract, expanding the range of treatable conditions. Recent innovations in smart, stimuli-responsive, and multifunctional nanocarriers, as well as combination therapies, are paving the way for personalized and precision medicine. However, the development and clinical translation of nanomedicines require rigorous safety assessments and regulatory oversight to ensure their efficacy and minimize potential risks. This review provides a comprehensive overview of the types, mechanisms, advantages, challenges, and emerging trends in nanotechnology-based drug delivery, highlighting its transformative impact on modern pharmaceutical science.

Keywords: Nanotechnology Drug delivery Pharmaceutical science Nanomedicine Targeted drug delivery

Introduction

Nanotechnology refers to the *engineering and manipulation of materials at the molecular or atomic scale*, typically involving structures sized between 0.1 and 100 nm. At this scale, materials exhibit unique physical, chemical, electrical, and optical properties, making them highly valuable for diverse applications in medicine and pharmaceuticals. The scope of nanotechnology in pharmaceuticals is broad, encompassing the development of nanomaterials, nanodevices, and nanosystems for drug delivery, diagnostics, imaging, tissue engineering, and the creation of artificial cells and smart implants [1].

Brief Overview of Nanotechnology in Pharmaceuticals

Within the pharmaceutical industry, nanotechnology is primarily used to design advanced drug delivery systems. These systems utilize nanoparticles, such as liposomes, dendrimers, polymeric nanoparticles, and metallic nanoparticles, to encapsulate, protect, and transport active pharmaceutical ingredients (APIs). Nanotechnology enables the delivery of organic and inorganic compounds, including proteins, antibiotics, chemotherapeutics, and vaccines. Its applications extend to gene therapy, cancer treatment, and the crossing of biological barriers, such as the blood-brain barrier, which are challenging for conventional drug formulations [2].

Importance of Targeted Drug Delivery and Bioavailability

A major advantage of nanotechnology in the pharmaceutical field is its ability to achieve targeted drug delivery. Nanoparticles can be engineered to deliver drugs directly to specific tissues or cells, improving therapeutic efficacy while minimizing adverse effects on healthy tissues. This targeted approach is particularly valuable for treating diseases such as cancer, where precision is critical for maximizing treatment benefits and reducing toxicity. Additionally, nanotechnology enhances bioavailability by improving the solubility and stability of poorly water-soluble drugs, thereby enabling more effective absorption and distribution within the body. Nanocarriers can also provide controlled and sustained drug release, further optimizing therapeutic outcomes [2].

Objectives and Structure of the Review

The primary objective of this review is to provide a comprehensive analysis of how nanotechnology is transforming pharmaceutical drug delivery, focusing on its impact on targeted therapy, bioavailability, and safety profiles. The review is structured as follows: Explores the types of nanocarriers and their mechanisms of action in drug deliver. The advantages of nanotechnology over conventional drug delivery methods, including improved efficacy and reduced side effects, are discussed. It highlights the key applications of nanotechnology in various therapeutic areas, such as oncology, infectious diseases, and gene therapy.

2. Basics of Nanotechnology in Drug Delivery

Nanocarriers: Definition and General Features

Nanocarriers are nanoscale materials, typically ranging from 1 to 1000 nanometers in diameter, that serve as advanced transport modules for delivering drugs or other therapeutic agents to specific sites within the body. Their remarkably small size enables them to access tissues and cellular compartments that are otherwise difficult to reach, thereby improving the pharmacokinetics, biodistribution, and overall efficacy of the drugs they carry. One of the key advantages of nanocarriers is their high surface area-to-volume ratio, which allows for highly efficient drug loading. Additionally, the tunability of their size, shape, and surface properties means that nanocarriers can be customized to suit the requirements of specific drugs and therapeutic targets. This flexibility facilitates controlled and sustained drug release, ensuring that medications are delivered at optimal rates and durations. Nanocarriers also offer the potential for site-specific, targeted delivery, which significantly reduces off-target effects and toxicity by concentrating the therapeutic agent at the desired location. Importantly, these systems are capable of carrying both hydrophilic and hydrophobic drugs, greatly expanding the range of therapeutics that can be effectively delivered using nanotechnology-based approaches [3, 4].

Types of Nanomaterials Used

Common types of nanocarriers in pharmaceutical applications include [5, 6, 7, 8].



Fig1: Types of nanomaterials

1. **Liposomes:** Spherical vesicles composed of one or more phospholipid bilayers capable of encapsulating both hydrophilic (in the aqueous core) and hydrophobic (within the bilayer) drugs. They are biocompatible and widely used for targeted drug delivery applications.

2. **Polymeric Nanoparticles:** Made from biodegradable polymers, these can be engineered for controlled drug release and surface modification with targeting ligands.

3. **Dendrimers:** Highly branched, tree-like macromolecules with well-defined structures and multiple surface functional groups, allowing for high drug loading and surface modification.

4. **Micelles:** Self-assembled colloidal structures formed by amphiphilic molecules (e.g., surfactants). They have a hydrophobic core for solubilizing poorly water-soluble drugs and a hydrophilic shell for stability in the biological fluids.

5. **Nanosuspensions:** Submicron colloidal dispersions of pure drug particles stabilized by surfactants. They enhance the solubility and bioavailability of poorly soluble drugs, such as curcumin.

6. Solid Lipid Nanoparticles (SLNs) are composed of solid lipids stabilized by surfactants. SLNs combine the advantages of liposomes and polymeric nanoparticles, offering good physical stability, biocompatibility, and the ability to encapsulate a wide range of drugs.

Mechanisms of Drug Release and Targeting

Drug Release Mechanisms

- **Diffusion-Controlled Release:** Drug molecules gradually diffuse out of the nanocarrier matrix into the surrounding biological environment.

- **Degradation-Controlled Release:** The nanocarrier material degrades (e.g., via hydrolysis or enzymatic action), releasing the encapsulated drug.

- **Stimuli-Responsive Release:** Drug release is triggered by specific stimuli, such as pH changes, temperature shifts, or the presence of certain enzymes, allowing for site- or condition-specific drug delivery [9,10].



Fig 2: Mechanism of drug release

Targeting Mechanisms

Passive Targeting: Utilizes the natural pathophysiology of certain tissues (e.g., tumors with leaky vasculature) to accumulate nanocarriers at the disease site through the enhanced permeability and retention (EPR) effect. This is especially effective in cancer therapy, where nanocarriers can preferentially accumulate in the tumor tissue.

Active Targeting: Involves modifying the surface of nanocarriers with ligands (e.g., antibodies, peptides, or small molecules) that specifically bind to receptors overexpressed on target cells (such as cancer cells). This enhances the specificity and uptake of drug-loaded nanocarriers by the intended cells.

Other Targeting Strategies include

- **pH-Specific Targeting:** Exploits the acidic environment of tumors or inflamed tissues to trigger drug release. Temperature-
- **Specific Targeting:** Utilizes localized hyperthermia to induce drug release from thermosensitive nanocarriers.



Fig 3: Mechanism of drug targeting

Enhancing Bioavailability through Nanotechnology

Solubility and Permeability Enhancement

Nanotechnology has revolutionized the enhancement of drug bioavailability, particularly for compounds with poor solubility and permeability. One of the most effective approaches involves the use of nanosuspensions, which are colloidal dispersions of pure drug particles stabilized by surfactants. These nanosuspensions are especially beneficial for hydrophobic drugs, as they significantly increase the drug's saturation solubility and dissolution velocity. The result is improved absorption and greater therapeutic efficacy, overcoming one of the primary limitations of many conventional drug formulations. Additionally, other nanocarrier systems such as polymeric nanoparticles, liposomes, and nanoemulsions can encapsulate poorly soluble drugs, shielding them from degradation and further enhancing their solubility and permeability across biological membranes. This encapsulation not only protects the active pharmaceutical ingredient from harsh environmental conditions but also facilitates its transport across cellular barriers, ensuring more efficient drug delivery to the target site.

Beyond improving solubility and permeability, nanocarriers are uniquely capable of overcoming major biological barriers that often limit the effectiveness of drug therapies. The blood-brain barrier (BBB), for example, is a highly selective membrane that restricts the entry of most drugs into the brain, posing a significant challenge in the treatment of neurological disorders. Nanoparticles can be engineered with specific surface modifications—such as coatings with polysorbate-80 or the attachment of targeting ligands—to exploit natural transport mechanisms like receptor-mediated transcytosis or adsorptive-mediated transport, thereby facilitating the passage of drugs across the BBB. Similarly, in the gastrointestinal (GI) tract, nanocarriers such as liposomes and nano emulsions offer protection for drugs against acidic and enzymatic degradation, enhance mucosal adhesion, and improve absorption through the intestinal epithelium. Surface modifications can be further employed to increase the penetration and retention of these nanocarriers at the absorption site, ensuring that more of the drug reaches systemic circulation. Collectively, these advances in nanotechnology are dramatically improving the bioavailability and therapeutic potential of a wide range of pharmaceutical agents [11, 12].

Nanoencapsulation for Sustained and Controlled Release

Nanoencapsulation is a cutting-edge strategy in drug delivery that involves enclosing therapeutic agents within nanocarriers such as polymeric nanoparticles, liposomes, or nanogels, which are specifically engineered to provide sustained and controlled release of drugs. This innovative approach offers several key advantages. Firstly, nanoencapsulated drugs often exhibit prolonged circulation times in the body, as the nanocarriers can evade rapid clearance by the immune system, thereby maintaining therapeutic drug levels for extended periods. Secondly, the release profile of the encapsulated drug can be precisely controlled by modifying the composition and structural characteristics of the nanocarrier, allowing for tailored drug delivery that matches specific therapeutic needs. This controlled release not only reduces the frequency of dosing but also enhances patient compliance. Additionally, nanoencapsulation provides a protective barrier for sensitive drugs, shielding them from premature degradation by environmental or physiological factors and ensuring that their activity is preserved until they reach the intended target site.

The benefits of nanoencapsulation are particularly evident in the case of poorly soluble drugs. For example, drugs such as itraconazole, simvastatin, and carbamazepine, which belong to BCS class II and have very low water solubility and poor oral bioavailability, have shown significantly improved dissolution rates, higher absorption, and enhanced therapeutic efficacy when formulated as nanosuspensions. Similarly, paclitaxel, a chemotherapeutic agent with notoriously poor solubility, has been successfully formulated as albumin-bound nanoparticles (as in Abraxane), enabling intravenous administration without the need for toxic solubilizing agents, improving tumor targeting, and reducing adverse side effects. Another notable example is amphotericin B, an antifungal drug whose encapsulation in liposomes (as in AmBisome) has not only improved its solubility but also reduced nephrotoxicity, making it a safer and more effective option for treating systemic fungal infections. Furthermore, various central nervous system (CNS) drugs have benefited from nanoencapsulation, as nanoparticles coated with targeting ligands or surfactants have demonstrated significantly enhanced permeability across the blood-brain barrier, resulting in higher brain concentrations and improved efficacy in preclinical models. These case studies underscore the transformative potential of nanoencapsulation in overcoming the limitations of conventional drug delivery, especially for challenging compounds with poor solubility and bioavailability [13, 14, 15].

Minimizing Side Effects and Toxicity

Site-Specific Action and Reduced Systemic Exposure

Nanocarriers are engineered to deliver drugs directly to the target tissue or organ, either through passive mechanisms (such as the enhanced permeability and retention effect in tumors) or active targeting (using ligands that bind to specific cell receptors). This site-specific action ensures that therapeutic agents accumulate predominantly at the disease site, which: Maximizes the local therapeutic effect. Minimizes exposure to healthy tissues. Significantly reduces systemic side effects, as seen in the use of nanocarriers for chemotherapy, where toxicity to healthy, fast-growing cells is greatly decreased.

Lower Dosing Requirements

Because nanocarriers enhance the local concentration of drugs at the target site and improve pharmacokinetics (such as half-life and biodistribution), they often enable therapeutic efficacy at lower doses compared to conventional formulations. This reduction in required dosage: Lowers the risk of dose-dependent adverse effects. Reduces treatment costs. Improves patient compliance by minimizing dosing frequency and side effects.

Biocompatibility and Biodegradability of Nanocarriers

A key design criterion for nanocarriers is biocompatibility the ability to perform their function without eliciting an adverse immune response or toxicity. Many nanocarriers are made from materials such as: Phospholipids (in liposomes), Biodegradable polymers (e.g., PLGA, chitosan), Solid lipids (in solid lipid nanoparticles).

These materials are generally biodegradable**,** meaning they break down into non-toxic metabolites that are safely eliminated from the body. This reduces the risk of long-term accumulation and chronic toxicity, making nanocarriers suitable for repeated or prolonged use.

Safety Assessments and Regulatory Considerations

Despite the significant therapeutic promise of nanocarriers, their development and clinical application come with unique safety and regulatory challenges that must be carefully addressed. Safety assessments for nanocarrier-based medicines require thorough evaluation of both acute and chronic toxicity, considering not only the encapsulated drug but also the carrier material itself. Preclinical and clinical studies must investigate the potential for nanocarriers to cause adverse effects over both short and long periods of use. Immunogenicity is another critical concern, as nanocarriers may trigger unwanted immune responses or hypersensitivity reactions, which could compromise patient safety. Additionally, understanding the biodistribution and clearance of nanocarriers is essential; researchers must determine how these systems distribute throughout the body, their metabolic pathways, and how they are ultimately excreted. This knowledge helps predict and mitigate off-target effects and long-term accumulation in non-target tissues.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established stringent requirements for the approval of nanocarrier-based pharmaceuticals. These agencies demand comprehensive data on the safety, efficacy, manufacturing quality, and environmental impact of such products. Detailed characterization of nanocarrier composition, particle size, surface properties, and stability is necessary to ensure consistency and predictability in clinical performance. Furthermore, rigorous assessments of pharmacokinetics, pharmacodynamics, and toxicology must be conducted in both animal models and human subjects to evaluate how nanocarriers behave in biological systems and to identify any potential risks. Long-term studies are also required to assess possible chronic effects and interactions with biological systems. Ultimately, toxicity and comprehensive efficacy studies are essential at every stage of development to ensure that nanocarrier-based medicines are both safe and effective for human use before they reach the market [16, 17, 18].

Emerging Trends and Innovations

Emerging trends in nanomedicine are increasingly focused on the development of smart nanocarriers—advanced drug delivery systems designed to respond to specific internal or external stimuli for precise, on-demand therapeutic release. Among these, pH-responsive nanocarriers are particularly notable, as they exploit the acidic microenvironment characteristic of many diseased tissues, such as tumors or intracellular compartments like lysosomes. By releasing drugs specifically in these acidic conditions (for example, at tumor sites with pH 6.5–6.8 or within lysosomes at pH 4.5–5.5), these carriers maximize therapeutic impact while minimizing side effects. pH-sensitive nanocarriers are also valuable for oral drug delivery, where they can release their payload at specific points along the gastrointestinal tract, adapting to the varying pH levels encountered.

Temperature-responsive nanocarriers represent another innovative approach, engineered to release their therapeutic payload when exposed to elevated temperatures. This can occur naturally in inflamed or cancerous tissues or be induced externally through localized hyperthermia. These systems often utilize polymers that undergo phase transitions at certain temperatures, enabling controlled and site-specific drug release. Similarly, magnetic-responsive nanocarriers incorporate magnetic nanoparticles, such as iron oxide, which can be directed to target sites using external magnetic fields. Once localized, these carriers can release their drugs in response to magnetic or thermal stimuli, offering highly localized therapy. This strategy is especially promising in cancer treatment, where magnetic fields can both guide the carrier and induce hyperthermia for synergistic therapeutic effects. Beyond these, smart nanocarriers can also be engineered to respond to light, ultrasound, redox conditions, or specific enzymes, further broadening their versatility and potential for controlled, site-specific drug delivery.

In addition to stimulus-responsive systems, hybrid and multifunctional nanocarriers are at the forefront of innovation. These carriers combine two or more types of materials—such as polymers, lipids, inorganic nanoparticles, or biological molecules—to integrate the unique advantages of each. Multifunctional nanocarriers are designed to fulfill several roles simultaneously: they can target specific cells or tissues through surface ligands, respond to multiple stimuli (such as pH and temperature), carry multiple drugs or therapeutic agents for combination therapy, and even enable diagnostic imaging. For example, graphene-based magnetic nanomaterials can combine magnetic targeting, mild hyperthermia, and pH-responsive drug release, providing powerful tools for cancer therapy. Such multifunctional systems not only enhance therapeutic efficacy and overcome multidrug resistance but also offer real-time monitoring of drug delivery, marking a significant step forward in personalized and precision medicine [19,20].

Combination Therapies Using Nanotechnology

Nanocarriers facilitate **combination therapies** by co-delivering multiple drugs, genes, or therapeutic agents within a single platform. This approach: Enhances synergistic therapeutic effects (e.g., chemo- and hyperthermia therapy) Reduces the likelihood of drug resistance Allows for precise control over the ratio and timing of drug release [21, 22, 23].

Conclusion

Nanotechnology has emerged as a transformative force in pharmaceutical drug delivery, offering solutions to many long-standing challenges in medicine. The unique properties of nanocarriers—such as their tunable size, surface characteristics, and ability to encapsulate a wide range of therapeutic agents—enable site-specific drug delivery, improved bioavailability, and reduced systemic toxicity. Advances in smart and multifunctional nanocarriers, as well as the integration of artificial intelligence in nanomedicine design, are driving the field toward more precise, efficient, and personalized therapies. Despite these promising developments, the translation of nanocarrier-based systems from laboratory to clinic necessitates thorough safety evaluations and adherence to stringent regulatory standards. Continued interdisciplinary research and innovation will be essential to fully realize the potential of nanotechnology in improving patient outcomes and shaping the future of pharmaceutical care.

References

1. Roy M, Roy A, Rustagi S, Pandey N. An overview of nanomaterial applications in pharmacology. Biomed Research International,2023:2023:4838043.
2. Mazayen ZM, Ghoneim AM, Elbatanony RS, Basalious EB, Bendas ER. Pharmaceutical nanotechnology: from the bench to the market. Future Journal of Pharmaceutical Sciences,2022:8(1):12.

3. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, *et al*. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Journal of Nanobiotechnology,2017:15(1):1–11.
4. Torchilin VP. Multifunctional nanocarriers. Advanced Drug Delivery Reviews,2012:64(Suppl):302–315.
5. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annual Review of Medicine,2012:63:185–198.
6. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology Therapeutics,2008:83(5):761–769.
7. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology,2007:2(12):751–760.
8. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. Journal of Occupational Medicine and Toxicology,2007:2:16.
9. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharmaceutical Research,2016:33(10):2373–2387.
10. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nature Materials,2013:12(11):991–1003.
11. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery therapeutics diagnostics and imaging. Nanomedicine,2012:8(2):147–166.
12. Ventola CL. The nanomedicine revolution: part 1: emerging concepts. Pharmacy and Therapeutics,2012:37(9):512–525.
13. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature Reviews Drug Discovery,2014:13(9):655–672.
14. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology,2015:6:286.
15. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles-based drug delivery systems. Colloids and Surfaces B Biointerfaces,2010:75(1):1–18.
16. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews,2013:65(1):36–48.
17. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari MR. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics,2018:10(2):57.
18. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioengineering Translational Medicine,2019:4(3):10143.
19. Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharmaceutica Sinica B,2016:6(4):268–286.
20. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discovery Today,2003:8(24):1112–1120.
21. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. Journal of Controlled Release,2010:141(3):265–276.
22. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology,2015:33(9):941–951.
23. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress challenges and opportunities. Nature Reviews Cancer,2017:17(1):20–37.